• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Madrigal Pharmaceuticals Inc.

    5/1/25 7:02:50 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDGL alert in real time by email
    mdgl-20250501
    0001157601FALSE00011576012025-05-012025-05-01

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ____________________
    FORM 8-K
    ____________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 1, 2025
    ____________________
    MADRIGAL PHARMACEUTICALS, INC.
    (Exact name of registrant as specified in its charter)
    ____________________
    Delaware001-3327704-3508648
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    Four Tower Bridge
    200 Barr Harbor Drive,
    Suite 200West Conshohocken, Pennsylvania
    19428
    (Address of principal executive offices)(Zip Code)
    (267) 824-2827
    Registrant’s telephone number, including area code
    (Former name or former address, if changed since last report)
    ____________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading
    Symbol(s)
    Name of each exchange
    on which registered
    Common Stock, $0.0001 Par Value Per ShareMDGLThe NASDAQ Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o




    Item 2.02 Results of Operations and Financial Condition.

    On May 1, 2025, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended March 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing.

    Item 9.01 Financial Statements and Exhibits.
    (d) Exhibits
    Exhibit
    Number
    Description
    99.1
    Press Release Dated May 1, 2025
    104Cover Page Interactive Data File (embedded within the Inline XBRL Document)

    2


    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    MADRIGAL PHARMACEUTICALS, INC.
    By:/s/ Mardi Dier
    Name: Mardi Dier
    Title: Executive Vice President and Chief Financial Officer
    Date: May 1, 2025
    3
    Get the next $MDGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDGL

    DatePrice TargetRatingAnalyst
    2/28/2025$236.00 → $422.00Neutral → Buy
    B. Riley Securities
    2/27/2025$400.00 → $405.00Buy
    H.C. Wainwright
    6/28/2024Neutral
    Cantor Fitzgerald
    6/11/2024$382.00Outperform
    Wolfe Research
    4/22/2024$150.00Underperform
    BofA Securities
    3/15/2024$155.00 → $270.00Sell → Neutral
    B. Riley Securities
    3/6/2024$382.00Buy
    Citigroup
    2/26/2024$155.00Neutral → Sell
    B. Riley Securities
    More analyst ratings

    $MDGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Baker Bros. Advisors Lp bought $22,516,577 worth of shares (101,792 units at $221.20) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      12/14/23 6:10:59 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baker Bros. Advisors Lp bought $7,548,616 worth of shares (34,578 units at $218.31) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      12/14/23 6:09:05 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baker Bros. Advisors Lp bought $12,128,340 worth of shares (64,350 units at $188.47) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      11/21/23 6:15:19 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    SEC Filings

    See more
    • SEC Form S-8 filed by Madrigal Pharmaceuticals Inc.

      S-8 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)

      6/20/25 4:22:14 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Madrigal Pharmaceuticals Inc.

      8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)

      6/20/25 4:04:08 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Madrigal Pharmaceuticals Inc.

      10-Q - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)

      5/1/25 8:53:57 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

      Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity

      3/14/24 3:35:50 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bate Kenneth was granted 715 shares, increasing direct ownership by 37% to 2,627 units (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      6/24/25 4:45:22 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Levy Richard S was granted 715 shares, increasing direct ownership by 3% to 21,197 units (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      6/24/25 4:42:30 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fouse Jacqualyn A was granted 203 shares, increasing direct ownership by 23% to 1,097 units (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      6/24/25 4:39:48 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care